SNORD19: SNORD19 is a box C/D snoRNA that is encoded in an intron of the gnl3 gene [PMC6984369]. It has been identified as a tumor immune infiltration-associated snoRNA in patients with colon cancer [PMC10050728]. The expression levels of SNORD19 are inversely proportional to the tumor immune infiltration score (TIIsno) [PMC8844792]. SNORD19, along with other snoRNAs (SNORD59A, SNORD63B, SNORD100, SNORD99, SNORD63, and SNORD12C), has significantly reduced expression levels in tumors and increased expression levels in immune cells [PMC8844792]. Low expression of SNORD19 is associated with poor prognosis in ovarian cancer patients [PMC6686521]. It has been found to be involved in splicing of two mRNAs and is not correlated with any mRNA [PMC6686521]. Additionally, SNORD19 has been identified as a significantly upregulated snoRNA in various tumors, including colon cancer and uterine corpus endometrial carcinoma (UCEC) [PMC10050728] [PMC6539089] [PMC7400997]. The expression pattern of SNORD19 may have potential for cancer subtyping [PMC6539089]. Overall, the research suggests that SNORD19 plays a role as a tumor immune infiltration-associated snoRNA and may have implications for prognosis and cancer subtyping.